Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients by unknown
RESEARCH ARTICLE Open Access
Prognostic influence of body mass index
and body weight gain during adjuvant
FOLFOX chemotherapy in Korean colorectal
cancer patients
Dae-Won Lee1, Sae-Won Han1,2*, Yongjun Cha1, Kyung-Hun Lee1, Tae-Yong Kim1, Do-Youn Oh1,2, Seock-Ah Im1,2,
Yung-Jue Bang1,2, Ji Won Park3, Seung-Bum Ryoo3, Seung-Yong Jeong3, Gyeong Hoon Kang4, Kyu Joo Park3
and Tae-You Kim1,2,5
Abstract
Background: Asian population has different body mass index (BMI) profile compared to Caucasian population.
However, the effect of obesity and body weight gain in Asian colorectal cancer patients treated with adjuvant
chemotherapy has not been studied thus far.
Methods: We have analyzed the association between disease-free survival (DFS) and obesity/body weight change
during treatment in Korean stage III or high-risk stage II colorectal cancer patients treated with adjuvant 5-fluorouracil/
leucovorin/oxaliplatin. BMI was classified according to WHO Asia-Pacific classification. Weight change was calculated by
comparing body weights measured at the last chemotherapy cycle and before surgery.
Results: Among a total of 522 patients, 35.7 % of patients were obese (BMI≥ 25 kg/m2) and 29.1 % were overweight
(BMI, 23–24.9 kg/m2) before surgery. 18.0 % of patients gained≥ 5 kg and 26.1 % gained 2–4.9 kg during the adjuvant
chemotherapy period. Baseline BMI or body weight change was not associated with DFS in the overall study
population. However, body weight gain (≥5 kg) was associated with inferior DFS (adjusted hazard ratio 2.04,
95 % confidence interval 1.02–4.08, p = 0.043) in overweight and obese patients (BMI ≥ 23.0 kg/m2).
Conclusion: In Korean colorectal cancer patients treated with adjuvant FOLFOX chemotherapy, body weight gain
during the treatment period has a negative prognostic influence in overweight and obese patients.
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Background
Colorectal cancer is one of the leading causes of cancer
incidence and death worldwide [1]. Although colorectal
cancer mortality is declining in the developed countries,
its incidence and mortality are increasing in other
countries, including Korea, which are probably due to
westernization of lifestyle [2, 3].
Body mass index (BMI) of ≥ 30.0 kg/m2 and 25.0–
29.9 kg/m2 are proposed by the World Health Organization
(WHO) for classification of obesity and overweight, re-
spectively [4]. The prevalence of obesity using this def-
inition is variable in different countries throughout the
world [5]. According to the definition, the prevalence
of obesity is higher than 20 % in many countries in
Western Europe and North America, whereas it is less
than 10 % in Asian countries including Korea and Japan
[5]. Considerable efforts have been made to identify re-
fined cut-offs of obesity for Asian countries in order to
better reflect the health risk and provide appropriate
action points [6, 7]. In Korea, BMI cut-off of 25 kg/m2
and 23.0–24.9 kg/m2 is used for the definition of obes-
ity and overweight, respectively [8, 9].
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While many epidemiology studies have shown that
obesity increases the risk of developing colorectal can-
cer, there has been conflicting data on the prognostic
impact of obesity in stage II and III colorectal cancer
patients [10–15]. Most of the previous studies were
conducted in Caucasian population and to our know-
ledge no study has investigated the effect of obesity in
Asian colorectal patients treated with adjuvant chemo-
therapy thus far. Considering the increase in the preva-
lence of colorectal cancer and obesity in some Asian
countries and the difference in BMI distribution be-
tween Asian and Caucasian, there is an urgent need for
data from Asian patients. In addition, very limited data
regarding body weight change after colorectal cancer
treatment and its impact on treatment outcome is
available [12]. Although body weight gain during the
period of adjuvant chemotherapy is frequently observed
in daily practice, its frequency and prognostic implica-
tion has not been studied in detail.
This study was undertaken to investigate how obes-
ity and body weight change during chemotherapy in-
fluences prognosis in Korean colorectal cancer patients
receiving adjuvant 5-fluorouracil, leucovorin, and oxalipla-
tin (FOLFOX) chemotherapy in order to provide prelim-
inary answers to the above questions.
Methods
Patients and treatment
This retrospective analysis was performed with Korean
patients who received curative surgery followed by adju-
vant FOLFOX chemotherapy at Seoul National University
Hospital (SNUH) (Seoul, Korea). Complete resection of
the tumor followed by 12 cycles of FOLFOX chemother-
apy is the current standard care in patients with stage III
colon cancer [16]. Eligibility criteria for this study were:
age over 18 years, adenocarcinoma histology, complete re-
section of the tumor with negative margins (from April
2005 to December 2011), stage III (any T, and N1 or
N2M0) or high-risk stage II (T3 or T4N0M0), completion
of at least 6 cycles of adjuvant FOLFOX, and adequate
organ functions. High-risk stage II was defined if they had
any of the following: T4 lesion, obstruction or perforation,
lymphovascular invasion, perineural invasion, or poorly
differentiated histology [17]. Patients with upper rectal
cancer were included if the patient did not receive pre- or
post-operative radiation. Only patients who received sur-
gery and chemotherapy at SNUH were included. Patients
were excluded if they had received previous chemotherapy
or radiotherapy for colorectal cancer, if they had signet
ring cell histology, distant metastasis or history of other
malignancy within 5 years. Chemotherapy regimen was
either FOLFOX-4 (from May 2005 to July 2009) or
modified FOLFOX-6 (from July 2009 to December
2011) [18]. Adjuvant chemotherapy was planned for a
total of 12 cycles and patients were assessed every 2
weeks during chemotherapy treatment, and then at
least every 6 months for 5 years. The post chemotherapy
period assessment included a medical history taking, phys-
ical examination, measurement of carcinoembryonic anti-
gen level, chest computed tomography, and abdominal
computed tomography. The diagnosis of recurrence was
made on the basis of imaging and, if necessary, biopsy.
From the electronic medical record system of SNUH, pa-
tients with diagnosis of colorectal cancer and prescription
of oxaliplatin were retrieved. Patients fulfilling the inclu-
sion and exclusion criteria by manual chart review were
included in the study cohort. The study protocol was
reviewed and approved by the institutional review board
of SNUH, Seoul, Korea [H-1210-016-430]. As this study
was retrospectively designed, informed consent was
waived by the IRB. The study database was last updated in
February 2014 (median follow-up duration 48 months).
This study was carried out in accordance with the recom-
mendations of the Declaration of Helsinki for biomedical
research involving human subjects.
Determination of BMI and body weight change
Trained nurses measured weight to the nearest 0.1 kg
and height to the nearest 0.1 cm. BMI was calculated by
dividing weight in kilograms by the square of height in
meters. Patients were classified according to the BMI
cut-offs proposed by WHO for Asian populations which
is used in Korea: underweight, BMI < 18.5 kg/m2; normal
range, 18.5–22.9; overweight, 23–24.9; obese I, 25–29.9;
and obese II, ≥ 30 [6]. Body weight and height measured
on the day of admission for colorectal cancer surgery
was used for calculation of baseline body weight and
BMI. For post chemotherapy body weight, we used the
body weight measured at the last cycle of chemotherapy.
Body weight change during treatment was calculated by
comparing post chemotherapy body weight with baseline
body weight.
Statistical analysis
The primary objective of this study is to investigate the
effects of BMI and body weight change during the pe-
riods of adjuvant FOLFOX chemotherapy on the treat-
ment outcome (disease-free survival, DFS) of colorectal
cancer patients. DFS was calculated from the date of op-
eration to the first date of documented recurrence or
the date of death from any cause. Data from patients
who were free of recurrence were censored at the date
of the last follow-up visit for DFS. Categorical variables
were compared using chi-square test or Fisher’s exact
test. Trend was analyzed using linear-by-linear associ-
ation test. DFS was calculated using the Kaplan-Meier
method and comparisons were made using the log-
rank tests. Hazard ratios (HR) were calculated using
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the Cox proportional hazard model and baseline charac-
teristics were adjusted by using backward stepwise model
including covariates with a probability value ≤ 0.20 in the
univariate analysis. Two-sided p-values of less than 0.05
were considered statistically significant. Statistical analysis
was performed with SPSS software for Windows, version
18.0 (SPSS, Chicago, IL, USA).
Results
Patient characteristics and BMI
Baseline characteristics of 522 patients included in the
present study are summarized in Table 1. The mean base-
line BMI of our cohort was 24.0 kg/m2 (male: 24.1 kg/m2,
female: 23.9 kg/m2). Based on the cut-offs proposed by
WHO for Asians [6], 10 patients (1.9 %) were underweight
(BMI < 18.5 kg/m2), 174 patients (33.3 %) were normal
weight (18.5–22.9 kg/m2), 152 patients (29.1 %) were
overweight (23–24.9 kg/m2), 171 patients (32.8 %) were
obese I (25–29.9 kg/m2) and 15 patients (2.9 %) were
obese II (≥ 30 kg/m2). Due to the limited numbers of pa-
tients with underweight or obese II, we classified patients
into 3 groups in further statistical analysis: normal or
underweight, ≤ 22.9 kg/m2; overweight, 23–24.9 kg/m2;
and obese, BMI ≥ 25 kg/m2.
Obese patients had higher proportion of older (≥ 65 years,
p = 0.028) and male (p = 0.095) population compared
with normal or underweight patients. The frequency
of stage III disease (p = 0.086) and MSI-high tumors
(p = 0.065) tended to be higher in obese patients.
Tumor location (proximal vs. distal) was similar among
the BMI groups (Table 1). According to the inclusion
criteria, all patients received at least 6 cycles of chemo-
therapy and 463 patients (88.7 %) completed planned
12 cycles of chemotherapy. There was no difference in
Table 1 Baseline characteristics
Body Mass Index
Total Normal or underweight Overweight Obese p-value*
≤ 22.9 kg/m2 23–24.9 kg/m2 ≥ 25 kg/m2
N (%) N (%) N (%) N (%)
Total 522 (100) 184 (35.2) 152 (29.1) 186 (35.6)
Age 0.028
< 65 years 366 (70.1) 138 (75.0) 108 (71.1) 120 (64.5) 0.42
≥ 65 years 156 (29.9) 46 (25.0) 44 (28.9) 66 (35.5) 0.028
Sex 0.094
Male 312 (59.8) 99 (53.8) 97 (63.8) 116 (62.4) 0.064
Female 210 (40.2) 85 (46.2) 55 (36.2) 70 (37.6) 0.095
Location 0.56
Proximal 181 (34.7) 63 (34.2) 49 (32.2) 69 (37.1) 0.70
Distal 341 (65.3) 121 (65.8) 103 (67.8) 117 (62.9) 0.57
T stage 0.17
T1 - 3 446 (85.4) 149 (81.0) 137 (90.1) 160 (86.0) 0.019
T4 76 (14.6) 35 (19.0) 15 (9.9) 26 (14.0) 0.19
N stage 0.96
N0 - 1 380 (72.8) 133 (72.3) 113 (74.3) 134 (72.0) 0.67
N2 142 (27.2) 51 (27.7) 39 (25.7) 52 (28.0) 0.96
Tumor stage 0.073
II, high-risk 78 (14.9) 37 (20.1) 16 (10.5) 25 (13.4) 0.016
III 444 (85.1) 147 (79.9) 136 (89.5) 161 (86.6) 0.086
Histology 0.15
MAC 27 (5.2) 12 (6.5) 9 (5.9) 6 (3.2) 0.82
Non-MAC 495 (94.8) 172 (93.5) 143 (94.1) 180 (96.8) 0.14
Microsatellite status (N = 517) 0.062
MSS/MSI-L 480 (92.8) 163 (90.1) 142 (93.4) 175 (95.1) 0.27
MSI-H 37 (7.2) 18 (9.9) 10 (6.6) 9 (4.9) 0.065
Abbreviations: MAC mucinous adenocarcinoma, MSS microsatellite stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high
*Upper row: linear-by-linear association test, middle row: Χ2 test of normal or underweight vs. overweight, lower row: Χ2 test of normal or underweight vs. obese
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chemotherapy completion rate according to BMI status
(p = 0.49).
Body weight change during chemotherapy
In the classification of body weight change, we adopted
the cut-off value of weight gain or loss of 2 kg and 5 kg,
which has been utilized in a previous study [12]. A total
of 44.1 % of patients gained body weight during adjuvant
chemotherapy (Table 2). Ninety-four patients (18.0 %)
gained 5 or more kilograms and 136 patients (26.1 %)
gained 2–4.9 kg. In contrast, 18.4 % of patients lost body
weight. Eighty patients (15.3 %) lost 2.1–5 kg and 16
patients (3.1 %) lost more than 5 kg.
Patients who had lower baseline BMI (p < 0.001) and
younger (< 65 years, p = 0.003) were more likely to gain
body weight (≥ 5 kg gain) during the adjuvant chemo-
therapy period. Location of the tumor did not influence
body weight gain (≥ 5 kg gain) during the adjuvant
chemotherapy period (proximal vs. distal = 20.4 % vs.
16.7 %, p = 0.29).
Impact of baseline BMI and body weight change on DFS
There was no significant difference in DFS according to
the baseline BMI groups (Fig. 1a). Three-year DFS were
90.0 % in obese patients, 84.5 % in overweight, and
89.0 % in normal or underweight (p = 0.34). In addition,
Table 2 Body weight change and baseline characteristics
Total > 5 kg loss 2.1–5 kg loss ± 2 kg 2–4.9 kg gain ≥ 5 kg gain p-value*
N (%) N (%) N (%) N (%) N (%)
Total 522 16 (3.1) 80 (15.3) 196 (37.5) 136 (26.1) 94 (18.0)
Baseline BMIa
Normal or underweight 184 2 (1.1) 16 (8.7) 63 (34.2) 46 (25.0) 57 (31.0) < 0.001
Overweight 152 3 (2.0) 23 (15.1) 58 (38.2) 45 (29.6) 23 (15.1) < 0.001
Obese 186 11 (5.9) 41 (22.0) 75 (40.3) 45 (24.2) 14 (7.5)
Age
< 65 years 366 11 (3.0) 52 (14.2) 128 (35.0) 97 (26.5) 78 (21.3) 0.006
≥ 65 years 156 5 (3.2) 28 (17.9) 68 (43.6) 39 (25.0) 16 (10.3) 0.003
Sex
Male 312 11 (3.5) 57 (18.3) 115 (36.9) 71 (22.8) 58 (18.6) 0.11
Female 210 5 (2.4) 23 (11.0) 81 (38.6) 65 (31.0) 36 (17.1) 0.67
Location
Proximal 181 3 (1.7) 30 (16.6) 66 (36.5) 45 (24.9) 37 (20.4) 0.40
Distal 341 13 (3.8) 50 (14.7) 130 (38.1) 91 (26.7) 57 (16.7) 0.29
T stage
T1 - 3 446 16 (3.6) 67 (15.0) 175 (39.2) 112 (25.1) 76 (17.0) 0.056
T4 76 0 (0.0) 13 (17.1) 21 (27.6) 24 (31.6) 18 (23.7) 0.16
N stage
N0 - 1 380 10 (2.9) 61 (16.1) 142 (37.4) 105 (27.6) 62 (16.3) 0.55
N2 142 6 (4.2) 19 (13.4) 54 (38.0) 31 (21.8) 32 (22.5) 0.10
Tumor stage
II, high-risk 78 2 (2.6) 9 (11.5) 24 (30.8) 29 (37.2) 14 (17.9) 0.15
III 444 14 (3.2) 71 (16.0) 172 (38.7) 107 (24.1) 80 (18.0) 1.00
Histology
MAC 27 1 (3.7) 5 (18.5) 6 (22.2) 5 (18.5) 10 (37.0) 0.180
Non-MAC 495 15 (3.0) 75 (15.2) 190 (38.4) 131 (26.5) 84 (17.0) 0.017**
Microsatellite status (N = 517)
MSS +MSI-L 480 14 (2.9) 73 (15.2) 186 (38.8) 124 (25.8) 83 (17.3) 0.33
MSI-H 37 1 (2.7) 7 (18.9) 9 (24.3) 10 (27.0) 10 (27.0) 0.14
Abbreviations: MAC mucinous adenocarcinoma, MSS microsatellite stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high
*Upper row: linear-by-linear association test, lower row: Χ2 test of ≥ 5 kg gain group vs. the others
**Fisher’s exact test of ≥ 5 kg gain group vs. the others
aNormal or underweight, ≤ 22.9 kg/m2; overweight, 23–24.9 kg/m2; and obese, BMI ≥ 25 kg/m2
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pattern of recurrence (local recurrence vs. distant metas-
tasis) was similar between each baseline BMI groups
(data not shown). We have also analyzed whether BMI
status has a prognostic role in subgroups of patients.
However, baseline BMI status was not associated with
DFS in any clinico-pathological subgroups including the
sex (data not shown).
We next evaluated the influence of body weight change
on DFS. Patients with body weight gain of ≥ 5 kg (3-year
DFS 82.8 %) showed tendency towards worse prognosis
compared to the other patients (3-year DFS 89.2 %;
p = 0.069) (Fig. 1b).
We hypothesized that body weight gain may have dif-
ferent patho-physiologic effect in overweight or obese
patients compared with normal or underweight pa-
tients. Therefore, we analyzed the association between
body weight gain (≥ 5 kg) and DFS stratified by baseline
BMI. In the normal or underweight patient population
(BMI ≤ 22.9 kg/m2), there was no significant difference
in DFS according to body weight gain (≥ 5 kg) (Fig. 2a).
In contrast, body weight gain (≥ 5 kg) was associated
with significantly worse DFS in overweight or obese pa-
tient population (BMI ≥ 23.0 kg/m2) (Fig. 2b, Table 3).
In the multivariate analysis, the poor prognosis associated
with weight gain (≥ 5 kg) in the overweight or obese
patient population was independent of other clinico-
pathologic prognostic factors (adjusted hazard ratio 2.04,
95 % confidence interval 1.02–4.08) (Table 4).
Discussion
In the present study, we have investigated the impact of
obesity and body weight change during chemotherapy on
the treatment outcome of Korean colorectal cancer pa-
tients receiving adjuvant FOLFOX chemotherapy. While
Fig. 1 Kaplan-Meier curves of disease-free survival according to baseline BMI (a) and body weight change (b). *p-value of weight gain≥ 5 kg vs. others
Fig. 2 Kaplan-Meier curves of disease-free survival according to body weight change stratified by baseline BMI. a Baseline BMI < 23 kg/m2, b
Baseline BMI≥ 23 kg/m2
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obesity and colorectal cancer has become one of the major
health problems in Asian countries including Korea, there
has been paucity of data regarding obesity among Asian
colorectal cancer patients [19, 20]. To our knowledge this
is the first Asian study to evaluate the prognostic role of
body weight change during adjuvant chemotherapy treat-
ment. We observed that baseline BMI is not associated
with DFS, but body weight gain (≥ 5 kg) during the adju-
vant chemotherapy has deleterious effect in overweight or
obese patients (BMI ≥ 23.0 kg/m2).
Although there has been some controversy in the
prognostic role of obesity in stage II or III colorectal
cancer patients, most data suggest negative prognostic
role of obesity. From the result of Adjuvant Colon
Cancer Endpoints (ACCENT) database, which is a
pooled resource of over 20,000 colon cancer patients
in adjuvant chemotherapy trials, obesity was associ-
ated with inferior outcome [15]. The adverse prognostic
effect was only observed in male patients, but there are
inconsistent data regarding gender-related prognostic dif-
ference of obesity [10, 14, 15].
However, these studies were all conducted in Western
countries where BMI distribution is different form
Asian population. In our study, 35.6 % of patients had
BMI ≥ 25.0 kg/m2 and only 2.9 % of patients had BMI ≥
30 kg/m2, which are similar to the incidence of Taiwanese
and Japanese colorectal cancer patients (4.2 and 1.5 %, re-
spectively) [19, 20]. In contrast, 53.6 % of patients have
BMI ≥ 25.0 kg/m2 and 17.6 % have BMI ≥ 30 kg/m2 in the
ACCENT study population [15]. Because of such a differ-
ence in BMI distribution between Asian and Caucasian
population, we could not directly apply the findings from
Western data to Asian colorectal cancer patients.
There are many studies evaluating the prognostic role
of weight gain after cancer diagnosis in breast cancer
patients [21–23]. Weight gain after breast cancer diag-
nosis was associated with higher rates of recurrence
and mortality [21]. However, only one study has evalu-
ated the prognostic role of weight change in stage III
colon cancer patients [12]. In contrast to breast cancer,
there was no prognostic role of weight gain in stage III
colon cancer patients in the Cancer and Leukemia
Group B 89803 study which examined the addition of
irinotecan to adjuvant 5-fluorouracil and leucovorin [12].
In the present study, while there was no prognostic role
of body weight change in the entire cohort, weight gain
was a negative prognostic factor in overweight or obese
patients. The discordant results may be attributable to
differences in ethnicity, BMI distribution, chemother-
apy regimen, and timing of body weight measurements.
Meyerhardt and colleagues compared body weights
measured at 4 months (in the middle of adjuvant
chemotherapy) and 14 months after surgery (6 months
after completion of chemotherapy) [12]. As we
Table 3 Univariate analysis of disease free survival among




Sex Male 1.46 (0.82–2.63) 0.20
Female 1
Age ≥ 65 years 1.09 (0.62–1.90) 0.77
< 65 years 1
Body weight change Gain≥ 5 kg 2.01 (1.01–3.99) 0.047
Others 1
Location Proximal 0.85 (0.48–1.50) 0.57
Distal 1
Stage III 1.32 (0.53–3.31) 0.55
II 1
T stage T 4 2.53 (1.36–4.72) 0.004
T 1–3 1
N stage N 2 2.96 (1.74–5.05) <0.001
N 0–1 1
Angiolymphatic invasion Present 3.87 (2.11–7.12) <0.001
Absent 1
Venous invasion Present 2.50 (1.26–4.98) 0.009
Absent 1
Perineural invasion Present 3.53 (2.05–6.07) <0.001
Absent 1
Histology MAC 1.35 (0.42–4.34) 0.61
Non-MAC 1
Microsatellite status MSI-H 0.70 (0.17–2.87) 0.62
MSS/MSI-L 1
Abbreviations: HR hazard ratio, CI confidence interval, MAC mucinous
adenocarcinoma, MSS microsatellite stable, MSI-L microsatellite instability-low,
MSI-H microsatellite instability-high
Table 4 Multivariate analysis of disease free survival among
patients with baseline BMI ≥ 23 kg/m2 (N = 338)
Adjusted HR (95 % CI) p-value
Body weight change Gain≥ 5 kg 2.04 (1.02–4.08) 0.043
Others 1
Angiolymphatic invasion Present 2.61 (1.37–4.94) 0.003
Absent 1
Perineural invasion Present 2.51 (1.43–4.38) 0.001
Absent 1
T stage T 4 1.99 (1.05–3.76) 0.035
T 1–3 1
N stage N 2 2.34 (1.35–4.06) 0.002
N 0–1 1
Abbreviations: HR hazard ratio, CI confidence interval
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measured body weight change during the adjuvant
chemotherapy period (before surgery and at the last
cycle of chemotherapy), body weight gain in the present
study may reflect the direct influence of weight gain on
chemotherapy sensitivity. Obesity leads to decreased
level of circulating adiponectin and increased level of
insulin-like growth factor 1 and leptin, which contrib-
ute to an increased risk of colorectal cancer [24]. More-
over, there are data that tumor expression of leptin is
associated with chemotherapy resistance [25]. There-
fore, it is tempting to speculate that body weight gain
during the adjuvant chemotherapy period may have al-
tered adipokine levels, which in turn contributed to
chemotherapy resistance. Dynamic changes in adipo-
kine levels might be more deleterious than the baseline
BMI and the deleterious effect is potentiated in the
higher BMI patients. However, because of limited num-
ber of patients, we could not evaluate effect size be-
tween weight gain and DFS. Future large prospective
study is needed to confirm our result.
Adding expensive targeted agents such as cetuximab
or bevacizumab to adjuvant chemotherapy have failed
to decrease recurrence in stage III colon cancer pa-
tients [26–29]. However, physical activity appears to re-
duce the risk of cancer recurrence and mortality in
stage III colon cancer patients enrolled in a randomized
adjuvant chemotherapy trial [30]. In patients receiving
adjuvant chemotherapy, life style modification may be a
cost effective approach to improve treatment outcome.
Future prospective study is needed to confirm whether
life style interventions can improve the outcome. In the
meantime, patients may be advised to maintain their
body weight during adjuvant chemotherapy period.
There are several limitations in our study. This study
was retrospectively designed that we lacked other import-
ant data of body habitus such as weight circumference, fat
distribution and lifestyle factors including diet, physical
activity and smoking that may have interaction with BMI
and weight change. Moreover, we do not have body weight
data during follow-up period after completion of chemo-
therapy. Therefore, it is essential to establish an Asian
prospective colorectal cancer cohort to overcome these
limitations and comprehensively study the impact of obes-
ity and lifestyle factors on prognosis of Asian patients. An-
other limitation is the relatively small sample size that we
could not perform more detailed analyses including sub-
analysis according to patient sex. However, the patient co-
hort was homogenous that all patients received surgery at
a high-volume center and received same adjuvant chemo-
therapy regimen. Lastly, we could not evaluate overall sur-
vival due to limited number of death events during the
relatively short duration of follow-up, albeit the 3-year
DFS has been demonstrated to have a good correlation
with 5-year overall survival in colon cancer [31].
Conclusions
Baseline BMI was not associated with prognosis in
Korean colorectal cancer patients treated with adju-
vant FOLFOX chemotherapy. However, body weight gain
during adjuvant chemotherapy had a negative prognostic
impact in overweight or obese patients. Until future pro-
spective study confirms our finding, overweight or obese
patients may be advised to maintain their body weight
during the adjuvant chemotherapy period.
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